K004002

FEB 1 4 2001

510(k) Summary
Safety and Effectiveness

This summary of safety and effectiveness information has been prepared in accordance with the requirements of SMDA 1990 and 21 CFR Part 807.92.

Name: **Address:**	Diagnostic Products Corporation 5700 West 96th Street Los Angeles, California 90045-5597
Telephone Number: **Facsimile Number:**	(310) 645-8200 (310) 645-9999
Contact Person:	Edward M. Levine, Ph.D. Director of Clinical Affairs
Device Name: **Trade:**	IMMULITE® CK-MB IMMULITE® 2000 CK-MB
Catalog Number:	LKMB1 (100 tests), LKMB5 (500 tests) L2KMB2 (200 tests). L2KMB6 (600 tests)
Common:	Reagent system for the determination of creatine kinase isoenzyme MB in plasma or serum.
Classification:	Class II device, 75-JHX (21 CFR 862.1215)
Manufacturer:	Diagnostic Products Corporation 5700 West 96th Street Los Angeles, California 90045-5597
Establishment Registration Number:	DPC's Registration Number is 2017183
Substantially Equivalent Predicate Device:	Diagnostic Products Corporation IMMULITE® CK-MB (LKCP)

Description of Device:

IMMULITE® CK-MB is a clinical device for use with the IMMULITE® Automated Immunoassay Analyzer.

IMMULITE® 2000 CK-MB is a clinical device for use with the IMMULITE® 2000 Automated Immunoassay Analyzer.

Intended Use of the Devices:

IMMULITE® CK-MB : For in vitro diagnostic use with the IMMULITE® Analyzer — for the quantitative measurement of creatine kinase isoenzyme MB (CK-MB) in heparinized plasma or serum, as an aid in patient management and the assessment of prognosis of myocardial infarction.

IMMULITE® 2000 CK-MB : For in vitro diagnostic use with the IMMULITE® 2000 Analyzer — for the quantitative measurement of creatine kinase isoenzyme MB (CK-MB) in heparinized plasma or serum, as an aid in patient management and the assessment of prognosis of myocardial infarction.

Method Comparison:

(LKMB) = 1.04 (LKCP) – 0.6 ng/mL
r = 0.993
Means: 38.7 (LKMB)
37.9 (LKCP)

Conclusion:

The data presented in this summary of safety and effectiveness is the data that the Food and Drug Administration used in granting DPC substantial equivalence for IMMULITE® CK-MB and IMMULITE® 2000 CK-MB.

Edward M. Levine

12/22/00

Edward M. Levine, Ph.D.
Director of Clinical Affairs

Date

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

FEB 1 4 2001

Edward M. Levine, Ph. D.
Director of Clinical Affairs
Diagnostic Products Corporation
5700 West 96th Street
Los Angeles, California 90045-5597

Re: K004002
Trade Name: IMMULITE ® and IMMULITE ® 2000 CK-MB
Regulatory Class: II
Product Code: JHX
Dated: December 22, 2000
Received: December 26, 2000

Dear Dr. Levine:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Steven Gutman

Steven I. Gutman, M.D., M.B.A.
Director
Division of Clinical Laboratory Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

510(k) Number (if known):_____
Device Name: IMMULITE® and IMMULITE ® 2000 CK-MB

Indications For Use: For *in vitro* use with the IMMULITE and IMMULITE 2000 Analyzer- for the quantitative measurement of creatine kinase isoenzyme MB (CK-MB) in heparinized plasma or serum, as an aid in patient management and the assessment of prognosis of myocardial infarction.

Dean Cooper
(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K004002

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

✓ Prescription Use
(Per 21 CFR 801.109)

OR

Over-The-Counter Use